Advertisement

Topics

Companies Related to "Colorectal Cancer Pipeline Review 2017 Report Updated 30062017" [Most Relevant Company Matches] RSS

21:49 EST 23rd February 2019 | BioPortfolio

Here are the most relevant search results for "Colorectal Cancer Pipeline Review 2017 Report Updated 30062017" found in our extensive corporate database of over 50,000 company records.

Showing "Colorectal Cancer Pipeline Review 2017 Report Updated 30062017" Companies 1–25 of 3,700+

Extremely Relevant

Report Card Coalition

Launched in 2004, the Colorectal Cancer Legislation Report Card initiative is supported by a coalition that includes American Cancer Society Cancer Action Network, American College of Gastroenterology, American Gastroenterological Association, American Society of Colon and Rectal Surgeons, American Society for Gastrointestinal Endoscopy, the Cancer Support Community, C3: Colorectal Cancer Coalitio...


Colonix Medical Limited

Colonix Medical Limited has pioneered and refined a new system for the early detection / screening of colorectal cancer and other bowel diseases such as IBD. This system can be used for both symptomatic and non symptomatic patients. Colorectal cancer is often referred to as ‘the silent killer’. If detected early, colorectal cancer treatments are effective and after treatment most sufferers ca...

Exact Sciences Corp.

Exact Sciences Corp. is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the ...


Relevant

Exact Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines ...

Targeted Diagnostics and Therapeutics

TDT has emerged as a leader in the development of innovative molecular diagnostics and therapeutics that can improve the quality of life of patients with colorectal cancer and gastrointestinal malignancies. Focused on innovative research and cutting edge technology, TDT has developed highly specific tests to detect colorectal cancer cells in lymph nodes from patients who have undergone surgical st...

Colorectal Cancer Coalition

This critical legislation will ensure that even in tight fiscal times, funding for life-saving federal colorectal cancer research programs can be sustained.

Targeted Diagnostics & Therapeutics, Inc

TDT has emerged as a leader in the development of innovative molecular diagnostics and therapeutics that can improve the quality of life of patients with colorectal cancer and gastrointestinal malignancies. Focused on innovative research and cutting edge technology, TDT has developed highly specific tests to detect colorectal cancer cells in lymph nodes from patients who have undergone surgical st...

Biothera Pharmaceuticals, Inc.

Biothera is a privately held biotechnology company developing Imprime PGG, a clinical stage immunotherapy drug that modulates key immune cells to orchestrate a coordinated immune response to cancer that involves both the innate and adaptive immune system. Proof of concept has been established from single-arm and randomized phase 2 studies in non-small cell...

Enterix Inc

Enterix Inc. is a US-based biotechnology company founded in 1997 that manufactures, markets, and distributes a leading-edge product for colorectal cancer screening. The company also uses this product to provide a colorectal cancer screening service. Enterix is addressing a large and rapidly growing market where there is a demonstrated need for an easy-to-use and cost-effective screening tool – a...

Biothera Pharmaceutical Inc.

Biothera is a privately held biotechnology company developing Imprime PGG, a late clinical stage immunotherapeutic drug candidate that modulates key immune cells to recognize and kill cancer. Proof of concept has been established from single-arm and randomized Phase 2 studies in non-small cell lung cancer (NSCLC), colorectal cancer, and chronic lymp...

Genesis Genomics Inc.

Cancer is the leading cause of pre-mature death in Canada, being responsible for almost 1/3 of all potential years of life lost. During their life-time, 2 in 19 women are expected to develop breast cancer, 1 in 18 will develop colorectal cancer, and 1 in 20 will develop lung cancer. Among men, 1 in 9 will develop prostate cancer during their life-time (National Cancer Institute of Canada, 2000).

Clinical Genomics Pty Ltd

Clinical Genomics is dedicated to improving patient outcomes through early detection of colorectal cancer. Clinical Genomics products span the full spectrum of colorectal cancer testing, lnSure® ONE™, a one sample fecal immunochemical test (FIT) for healthy adults to detect lower GI bleeding, and COLVERA®, a proprietary liquid biopsy blood test ...

C3: Colorectal Cancer Coalition

Expert Opinion

The Expert Opinion series of review journals provides systematic and authoritative analysis to support every stage in the pharmaceutical pipeline. Our expertly crafted review articles enable the R&D community to access and track the key advances that lead to the creation of new drugs.

CancerDecisions®

If you or a loved one are dealing with cancer, The Moss Reports is an important ally in your corner. You can securely order a Moss Report right now by downloading it in electronic format from this Web site and having it delivered to your email box within minutes. Click here to order or to see a list of our 200+ Moss Reports, Dr. Moss's introductory letter, or a sample Table of Contents.Created by ...

COLORECTAL CANCER ASSOCIATION OF CANADA

Fight Colorectal Cancer

Headquarters Address:

U3 Pharma AG

U3 Pharma AG is an emerging leader in targeted cancer drug development. The company has produced a pipeline of novel targeted therapeutics based on the ground-breaking discoveries made by its founder - Prof. Axel Ullrich.U3 Pharma´s vision is to provide clinical oncologists with an arsenal of new targeted therapeutics that can be employed to turn cancer. an often life threatening disease, into a ...

Dynavax Technologies

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative therapeutic products to treat and prevent infectious diseases, allergies, and cancer. Our versatile, proprietary approaches alter specific immune responses by activating a unique receptor called Toll-Like Receptor 9 (TLR9) found on certain immune system cells. To target TLR9, we are using immunostimulat...

eMedicine.com, Inc

Launched in 1996, www.eMedicine.com comprises the largest and most current Clinical Knowledge Base available to physicians and other healthcare professionals. eMedicine's subscription site for institutions is www.iMedicine.com. Nearly 10,000 physician authors and editors contribute to the eMedicine Clinical Knowledge Base, which contains articles on 7,000 diseases and disorders. The evidence-based...

Informa Healthcare - Expert Opinion series

The Expert Opinion series of review journals provides systematic and authoritative analysis to support every stage in the pharmaceutical pipeline. Our expertly crafted review articles enable the R&D community to access and track the key advances that lead to the creation of new drugs

National Coalition for Quality Colorectal Cancer Screening and Care

Austrian Breast & Colorectal Cancer Study Group (ABCSG)

Five Prime Therapeutics

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases. Five Prime has developed a library of more than 5,600 human extracellular proteins. Five Prime screens this comprehensive library with its proprietary high-throughput protein screening technologies to identify new targets f...

Synergys Biotherapeutics

Synergys is an early stage company developing multifunctional anti-vascularization antibody drugs targeting VEGF-alternative pathways. The Company’s most advanced product candidate, Anti-EGFR‐TAP (SYN001) was derived from its platform technology termed A‐TAP (Antibody-Targeted Anti-Vascularization Payload). SYN001 is currently in preclinical ...


More From BioPortfolio on "Colorectal Cancer Pipeline Review 2017 Report Updated 30062017"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks